(Q50557603)

15 March 2018

title

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. (English)

1 reference

15 March 2018

0 references

Nelson Cheinquer

1

1 reference

15 March 2018

Hugo Cheinquer

series ordinal

2

1 reference

15 March 2018

Fernando H Wolff

series ordinal

3

1 reference

15 March 2018

Silvia Coelho-Borges

series ordinal

4

1 reference

15 March 2018

publication date

1 September 2010

1 reference

15 March 2018

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

published in

1 reference

15 March 2018

volume

14

1 reference

15 March 2018

issue

5

1 reference

15 March 2018

page(s)

457-461

1 reference

15 March 2018

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Prevention of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970093-3

7 January 2021

10.1016/S1413-8670(10)70093-3

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018